Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 10,049	$ 20,818
Prepaid expenses and other current assets	5,774	9,519
Total Current Assets	15,823	30,337
Property and equipment, net	482	494
Deposits and other assets	26	14
Total Assets	16,331	30,845
Current Liabilities:
Accounts payable	4,556	4,413
Accrued expenses	1,841	297
Warrant liabilities	7,552	10,567
Accrued employee benefits	1,174	277
Deferred rent	50	21
Total Current Liabilities	15,173	15,575
Long term deferred rent	227	267
Total Liabilities	15,400	15,842
Commitments and Contingencies
Equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized, 91,351,068 issued and 91,269,586 outstanding and 90,908,234 issued and 90,826,752 outstanding	91	91
Additional paid-in capital	163,508	160,739
Accumulated deficit	(161,305)	(144,779)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	2,294	16,051
Non-controlling interest	(1,363)	(1,048)
Total Stockholders' Equity	931	15,003
Total Liabilities and Stockholders' Equity	$ 16,331	$ 30,845